BeiGene Corporate Presentation

May 4, 2023
Disclosures

Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date
hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding BeiGene’s research, discovery, and pre-
clinical and early-stage clinical programs and plans; recent clinical data for BeiGene’s product candidates and approvals of its medicines; the conduct of late-stage clinical
trials and expected data readouts; additional planned commercial product launches; and the advancement of and anticipated clinical development, regulatory milestones
and commercialization of BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of
various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not
support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing
approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection
of intellectual property for its technology and medicines; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s
limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete
the development and commercialization of its drug candidates and achieve and maintain profitability; the impact of the COVID-19 pandemic on BeiGene’s clinical
development, commercial, regulatory and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent
periodic report filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All
information in this presentation is as of the date of this presentation, and BeiGene undertakes no duty to update such information unless required by law.

Some of the clinical data in this presentation relating to BeiGene’s investigational drug candidates is from pre-clinical studies or early phase, single-arm clinical trials. When
such data or data from later stage trials are presented in relation to other investigational or marketed drug products, the presentation and discussion are not based on head-
to-head trials between BeiGene’s investigational drug candidates and other products unless specified in the trial protocol. BeiGene is still conducting pre-clinical studies and
clinical trials and, as additional patients are enrolled and evaluated, data on BeiGene’s investigational drug candidates may change.

This presentation and the accompanying oral presentation contain data and information obtained from third-party studies and internal company analysis of such data and
information. BeiGene has not independently verified the data and information obtained from these sources. Forward-looking information obtained from these sources is
subject to the same qualifications noted above.

2
 $1.3B in annual product revenue
~40 offices, 9,400+ colleagues 3,500+ global commercial team
$3.8B cash balance*
on 5 continents 16 approved products

950+ oncology 2,700 global clinical In-house manufacturing plus

research team development & medical affairs U.S. expansion under construction
Founded team
2010

@BeiGeneGlobal BeiGene 60+ pre-clinical programs, ~50 assets in clinical and ~20 industry
the majority with commercial stages collaborations
first-in-class potential
Numbers as of March 2023

3
 Building Strategic and Sustainable Competitive Advantages

Innovation with speed and lower cost to better serve patients around the world

Our Five Sustainable Competitive Advantages:

1 2 3 4 5

• 950+ research team with • Cost and time-advantaged • 3,300+ in China including • Cornerstone commercial • 500+ people in 3 mfg.
entrepreneurial culture​ clin dev medical affairs, medicines with huge sites; In-house capabilities
competitively positioned, global potential, BTKi and bring cost, agility to
• 2,300 clinical development
• Heme, solid tumor and I&I science-based leadership PD-1 internal and external
colleagues​
franchise including 60+ programs​
preclinical programs, • Global development, • 500+ competitive footprint • Complemented by deep  Suzhou
~50% with first-in-class Asia inclusive (45+ in North America & Europe and innovative clinical
 Guangzhou
potential geographies) portfolio
• Expanding presence in  Hopewell, NJ
• ~50 assets in clin & comm
• Focus on innovative multiple countries/ regions,
stage • Capability to manufacture
modalities in oncology and including underserved
both small molecules and
I&I • 20,000+ subjects enrolled areas
biologics

4
 T R A N S L AT I N G S C I E N C E T O I M P R O V E A C C E S S A N D
Trials Span

45
A F F O R D A B I L I T Y B Y C H A L L E N G I N G T H E S TAT U S Q U O

+
Enrollment by Geography

Countries
& Regions 16%

20K
8%

+ 14%
53%

9%
People Enrolled in

110
Clinical Trials
+
China Americas Australia APAC-ex Australia EMEA

5
 Positioned to Deliver on Significant Revenue Growth

Key Drivers
Global Product Revenue
U.S. 410,291 • Significant revenue growth driven
BRUKINSA
approval in CLL
by BRUKINSA

• Growing share of PD1/L1 class

in China, expanding top
1st BRUKINSA leadership position
Began approval (U.S.);
1st BRUKINSA
tislelizumab
commercializing approval (U.S.),
approved in
tislelizumab
• Continued revenue growth for
Celgene
products in China
approved in China partner medicines
China
56,892
• Execution of commercial
launches for late-stage pipeline
8,822
• Continued global commercial
Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
expansion
2017 2018 2019 2020 2021 2022 2023

Dollars in thousands

6
Differentiated Biological Hypothesis and First-in-Class
Programs Based on Deep Oncology Insights from the Bench
Differentiated
BTK - Higher exposure, better selectivity, targeted inhibition biological hypothesis

Potential first-in-class,
PD-1 - Fc function silenced or first wave

TIGIT - Intact Fc function, first wave

BCL2 - Higher potency, increased selectivity, and shorter half life

BTK Degrader - Potentially first-in-class, eliminates both kinase and

non-kinase function of BTK, should inhibit BTKi resistant strains

OX-40 - Only OX-40 Ab not interfering with OX-40 ligand binding

HPK-1 - Potentially first-in-class intracellular checkpoint inhibitor

CEA-41BB - Potentially first-in-class immune activator,

converting immune cold tumor to hot
7
Productive Research and Path to Global Oncology Leadership

Entering a New Era of Discovery

2024+
2021-2023 10 New
Prolific First Decade
Molecules
HPK-1 BTK-Targeted CDAC
in the Clinic
TYK2
2016 - 2020 CEA x 4-1BB bispecific Expected
SMAC mimetic
Annually
TIM-3
2013 - 2015 4+ NMEs in 2023
TIGIT OX40
BRAF PARP* SM and mAb: 20+ New CDAC: Total 7+
BCL-2 PI3Kd
programs programs
BTK* PD-1*
ADC: 10+ TAAs BsAb/TsAb: 10 new
programs
Pro-Cytokine
mRNA Therapy
Cell therapy: CAR-NK
and more
*Approved 2019-2021
SM, Small Molecule; mAb, Monoclonal Antibody; ADC, Antibody Drug Conjugate; TAA, Tumor Associated Antigen; CDAC, Chimeric Degradation Activating 8
Compound (targeted protein degradation); BsAb, Bispecific Antibody; TsAb, Trispecific Antibody; CAR-NK, Chimeric Antigen Receptor-Natural Killer Cell, NME, New Molecular Entity
Oncology Research Expertise With Proven Track Record
of Innovation

Research Team Expansion Global Research Headcount

Science-driven culture from inception Highly productive 950+ scientists

Prolific in first decade and expected to be more productive • Low-cost and high-efficiency
in the years ahead
• Quality validated by clinical results 1000
• 60+ preclinical programs, ~50% with first-in-class or best-in- and global partnerships
class potential 900
• Expertise across multiple 800
• A burst of new clinical molecules expected in the next few
scientific disciplines
years, 10+ INDs per year expected starting in 2024 700

# of scientists
Expanding new capabilities and talent base with intent to 600
expand into the US 500
• Invest in new modalities including CDAC, BsAb / TsAb, 400
ADC, NK cell therapies, pro-cytokines
300
• Investing in new capabilities and driving efficiencies through
200
portfolio management
100
Quality validated by clinical results, global approvals, and
major pharma/biotech partnerships that have generated $1.4bn 0
2011 - 2015 2015 - 2019 2021 2022
collaboration fees

9
BRUKINSA Superiority to Ibrutinib Core to Hematology Franchise*

Broad Global Demonstrating

Best-in-Class Clinical Program Clinical
Hypothesis 4,900+ Subjects Advantages

• Complete and sustained • 35 trials across 29 • First and only BTKi to

target inhibition in disease markets demonstrate superior
originating tissues efficacy versus ibrutinib –
• Two head-to-head studies
ORR and PFS
• Maintains therapeutic versus ibrutinib – 800+
concentrations over subjects • Favorable safety versus
24 hours ibrutinib with improved
• Comprehensive label vs.
cardiac profile - Afib, and
• Equally or more selective next generation BTKi
0% vs 1.9% sudden cardiac
than any approved BTKi (approved in CLL, MCL,
death in ALPINE
WM, MZL)
• Dosing flexibility – QD / BID

*Superior to ibrutinib in ORR & PFS for R/R CLL in ALPINE trial.
10
 ALPINE: BRUKINSA PFS & ORR Superiority to Ibrutinib in R/R
CLL/SLL 2022 ASH Late Breaker & Concurrent NEJM Manuscript
BRUKINSA PFS by IRC Significantly Superior to Ibrutinib BRUKINSA Improved PFS in Patients with del(17p)/TP53mut

Data cutoff: 8 Aug 2022. Brown J et al. NEJM 2022. DOI: 10.1056/NEJMoa2211582
11
 BRUKINSA: Establishing Leadership with Best-In-Class BTKi

($MM)
BRUKINSA Global Revenues • BTKi is the cornerstone therapy and the standard
of care for non-Hodgkin’s lymphoma
$250
$211
$200 $176 • The BTKi market was $8.4bn in 2022
$155
$150 $129 • CLL is the largest indication for BTKi, accounting
$104
$100
$88 for 80% of the market
$66
$42
$50
$7 $16 $18 $22 • Given its best-in-class profile, as demonstrated in
$0 head-to-head clinical trials for CLL, BRUKINSA is
Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 well positioned to become the leading BTKi
'20 '20 '20 '21 '21 '21 '21 '22 '22 '22 '22 '23

Successful approvals in CLL are unlocking BRUKINSA’s

value globally and anticipated to drive revenue growth
12
 Tislelizumab Well Positioned for Global Success

1 Mechanistically
differentiated, Fc-γ
2 Realizing Impact from
favorable labels and 3 Broad clinical program, including:
• 21 registration-enabling clinical
NRDL coverage in China trials
receptor sparing, and
• Achieved #1 value market
multiple share in China despite late • 12,100+ subjects enrolled in
combinations under to market; future filings in clinical trials in 30+ countries and
study
ROW regions, with 4,000+ from outside
of China

4 Commitment to
quality, global 5 Future global approvals in more
indications, and combinations
Collaboration with
Novartis
manufacturing • 10 approved indications in China: R/R cHL, R/R UC, 1L • Acceleration of global
Sq, 1L non-Sq NSCLC, 2L/3L HCC and 2L/3L NSCLC, development in Novartis
• Built state-of-the-art facility 2L/3L MSI-H or dMMR solid tumors, 2L ESCC, 1L NPC,
in Guangzhou, building 1L G/GEJ territory: North America,
toward 200,000L of Europe, and Japan
• 1 filing in the U.S.: 2L ESCC*, 2 filings in Europe:
biologics capacity NSCLC & ESCC, filings in Australia and UK in NSCLC • Further explore
• Collaboration with one of & 2L ESCC, and 2 in China in 1L ESCC & 1L HCC. combination opportunities
the world’s leading • 11 other pivotal or potentially registration-enabling with Novartis pipeline
biologics manufacturers studies ongoing; compelling breadth of combinations
e.g., ociperlimab, sitravatinib, zanidatamab, etc. • Eligible for up to $1.5 billion
25 global biologics
manufacturing • IO combination trials underway to drive success collaboration revenue from
approvals Novartis
13
*Subject to regulatory inspections which have been delayed due to COVID-19 travel restrictions. cHL = classical Hodgkin’s lymphoma; CR = complete response; dMMR = Deficient Mismatch Repair; ESCC = Esophageal Squamous-Cell Carcinoma; HCC = hepato-
cellular carcinoma; MSI-H = microsatellite instability-high; NRDL = China National Reimbursement Drug List; non-Sq: non-squamous; NPC = Nasopharyngeal carcinoma; NSCLC = non-small cell lung cancer; R/R = relapsed/refractory; UC = urothelial carcinoma
 BeiGene’s Internal Discovery Pipeline
Late-Stage P1 P2* P2** P3 Filed Early-Stage P1a P1b P2* P2** P3
Zanubrutinib (BTK inhibitor) Surzebiclimab (BGB-A425, anti-TIM-3)
TN MCL, R/R MZL (+rituximab) Solid tumors (+/- tislelizumab)
R/R FL (+obinutuzumab)
BGB-A445 (anti-OX40)
R/R DLBCL#, Ibrutinib/acalbrutinib intolerant CLL/SLL#1, B-cell malignancies# (mono)
Solid tumors (+tislelizumab)
R/R DLBCL# (+lenalidomide)
Lupus nephritis# (mono) Lifirafenib2 (RAF Dimer)
Tislelizumab (anti-PD-1) [Global ex-Novartis territory†] B-Raf- or K-RAS/N-RAS-mutated solid tumors (+mirdametinib)
1L ESCC (+chemo), 1L HCC (mono) BGB-32453+ (B-Raf inhibitor)
Neo/adjuvant NSCLC#, 1L UBC, 1L SCLC# (+chemo), early ESCC# (+CRT)
Solid tumors
MSI-H/dMMR CRC# (mono),1L ESCC&GC/GEJ, neo ESCC# (+chemo)
1L HCC (+lenvatinib), solid
# tumors# (+fruquintinib, +lenvatinib) BGB-10188 (PI3-Kδ inhibitor)
R/R cHL# (mono) B-cell malignancies; Solid tumors (mono; +tislelizumab; +zanubrutinib)
R/R cHL (mono) BGB-15025 (HPK1 inhibitor)
Pamiparib (PARP 1/2 inhibitor) Advanced solid tumors (+/- tislelizumab)
2L PSOC maintenance (mono)#
BGB-23339 (TYK2 inhibitor)
1L GC maintenance (mono)
Solid tumors (+TMZ (chemo)) Dose escalation in healthy subjects

Ociperlimab (anti-TIGIT) BGB-16673 (BTK-targeted PROTAC)

1L PD-L1+ stage IV NSCLC (+tislelizumab), PD-L1+ LA NSCLC (+tislelizumab+cCRT) Dose escalation

2L PD-L1+ ESCC, 2L+ CC (+tislelizumab), 1L HCC (+tislelizumab+BAT1706) BGB-24714 (SMAC^ mimetic)
1L LS-SCLC(+tislelizumab+cCRT), 1L NSCLC (+tislelizumab+chemo)
Dose escalation
Solid tumors (+tislelizumab)
R/R DLBCL# (+tislelizumab/rituximab) BGB-B167 (CEA x 4-1BB bispecific)

BGB-11417 (BCL-2 inhibitor) Dose escalation

R/R MCL, R/R CLL# (mono)

NHL, AML/MDS, MM Heme Solid Tumor Heme + Solid Non-Oncology

*Some indications will not require a non-pivotal Phase 2 clinical trial prior to beginning pivotal Phase 2 or 3 clinical trials; **Confirmatory clinical trials post-approval are required for accelerated
approvals; † Novartis owns commercial rights in United States, Canada, Mexico, the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan.
^SMAC = second mitochondrial-derived activator of caspase. # single-country trial. 1. BGB-3111-215 trial in previously treated B-cell lymphomas intolerant of prior BTKi treatment. 2. In
collaboration with SpringWorks Therapeutics. 3. Developed by MapKure, LLC, jointly owned by BeiGene and SpringWorks. MapKure and is currently developing BGB-3245 under an exclusive
license from BeiGene.
BCL-2i Program Summary

• BGB-11417 is a BCL2 inhibitor with potential to be best in class given higher potency and increased
selectivity as well as shorter half-life compared to venetoclax that can potentially lead to improved
efficacy and safety.
• Broad development plan initiated in CLL, NHL (including WM, MCL, MZL), AML, MDS
and MM.
• With 400+ patients treated to date in 4 phase 1 studies, no safety concerns.
• Encouraging early efficacy in all indications eg. durable and deep responses seen in CLL at all doses
tested- longer follow up is needed for higher dose. AML patients on BGB-11417 + azacitidine have
high rates of blast clearance with doses as low as 40mg and responses are durable.
• Two trials with registrational intent:
– R/R MCL after failure of BTKi
– R/R CLL after failure of BTKi
• Broad registrational opportunities

15
 BGB-16673: BTK Chimeric Degradation Activating Compound
for B-Cell Malignancies Showing Promise in Clinic
Deep, Rapid & Sustainable BTK Degradation Observed
at the First Dose Level in Phase 1 Study (50 mg)
• Targeting BTK via an alternative mechanism

• New generation BTK inhibitor to enhance BTK

expertise
– To overcome BTK kinase inhibitor resistance

– To destroy non-kinase (scaffolding) function

• BGB-16673, BeiGene’s first CDAC molecule advanced

to clinic
– 2.5 years from program initiation to clinic
BGB-16673 can Overcome both Zanubrutinib
– Good pharmacological properties and LOXO-305 Resistance
• No IMiD activity
TMD8-BTK (WT) TMD8-BTK (C481S) TMD8-BTK (L528W)
120 120 120 BGB-16673
• Highly potent and selective LOXO-305
80 80

Inhibition (%)
Zanubrutinib

Inhibition (%)
80

%Inhibition
• Good oral bioavailability and long t1/2 40
40
40

0
0
– Complete BTK degradation and clinical response -2 0 2 4
0

-2 0 2 4 -2 0 2 4
observed at the first dose level, 50 mg Log [Drug] (nM) Log [Drug] (nM) Log [Drug] (nM)

16
IMiD: immunomodulatory imide drug
 Clinical Pipeline from External Collaboration
Commercial
Program / indication P1a P1b P2* P2** P3 Filed rights Partner
Sitravatiniba (multi-kinase inhibitor) - 2/3L NSCLC (+ tislelizumab) Asia ex-Japan, AU, NZ Mirati

Sitravatiniba - HCC#, GC/GEJC# , 2/3L ESCC# (Mono, + tislelizumab) Asia ex-Japan, AU, NZ Mirati

Sitravatiniba - Solid Tumors (Mono, + tislelizumab) Asia ex-Japan, AU, NZ Mirati

Zanidatamabb (HER2, bispecific antibody) - 1L HER2+ GEA (+ chemo ± tislelizumab) Asia ex-Japan, AU, NZ Zymeworks

Zanidatamabb - Biliary tract cancers (Mono) Asia ex-Japan, AU, NZ Zymeworks

ZW49 (HER2, bispecific ADC) - HER2-expressing cancers Asia ex-Japan, AU, NZ Zymeworks

LBL007 (LAG-3) - Solid Tumors (+ tislelizumab) Ex-China Nanjing Leads Biolabs

SEA-CD70 (anti-CD70) - MDS, AML Asia ex-Japan, AU, NZ Seagen

AMG 176 (Mcl- 1) - Hematologic malignancies China Amgen

Sotorasib (KRAS G12C) - Solid tumors, CRC, NSCLC China Amgen

Tarlatamabc (DLL3 x CD3) – SCLC, Neuroendocrine Prostate Cancer1 China Amgen

AMG 509 (STEAP 1 x CD3) - Prostate cancer China Amgen

AMG 199c (MUC17 x CD3) - GC/GEJC, Colorectal, and Pancreatic Cancers China Amgen

Acapatamabc (PSMA x CD3) - Prostate cancer, NSCLC China Amgen

AMG 256 (Anti-PD-1 x IL21 mutein) - Solid tumors China Amgen

ABI-H3733 (HBV core inhibitor) - Chronic Hepatitis B virus Greater China Assembly Bio

Heme Solid Tumor Non-oncology

a. Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPPHIRE trial in non-Sq NSCLC; b. ZW25; c. Half-life extended BiTE® molecule; # single-country trial.
*Some indications will not require a non-pivotal Phase 2 clinical trial prior to beginning pivotal Phase 2 or 3 clinical trials; **Confirmatory clinical trials post-approval are required for accelerated
approvals. 1. This is a Phase 1 trial.
Growing Commercial Portfolio: 16 Approved Assets

Product Lead Indications Mechanism of Action Regulatory Status Our Commercial Rights Partner

Approved in more than 65

U.S.: CLL,R/R MCL1, WM & R/R MZL1; China: R/R MCL2, R/R
BTK inhibitor markets, incl. U.S., China, EU Global NA
CLL/SLL2 & R/R WM2; EU3: CLL, WM & MZL
and other markets

China:1L Squamous and Non-Squamous NSCLC, 2/3 L NSCLC, R/R Approved in China​ Outside North America,
Tislelizumab classical Hodgkin’s lymphoma2, 2/3 L HCC2, R/R PD-L1+ UC2, 2L Anti-PD-1 antibody BLA Accepted in U.S.4 Japan, UK, AU, EU and six
ESCC, MSI-H or dMMR solid tumors2, 1L NPC, 1L G/GEJ MAA accepted in EU4 other European countries

3L BRCA-mutated ovarian cancer2 PARP Inhibitor Approved in China Global

Anti-RANK ligand
Giant cell tumor of bone8, Skeletal Related Events (SREs)7 Approved in China Mainland China
antibody

Anti-CD19 x anti-CD3
R/R Acute lymphocytic leukemia7 bispecific T-cell Approved in China Mainland China
engager (BiTE®)

R/R Multiple myeloma7 Proteasome inhibitor Approved in China Mainland China

R/R adult multiple myeloma, newly diagnosed multiple myeloma, Anti-angiogenesis,

Approved in China Mainland China
previously treated follicular lymphoma immuno-modulation

Myelodysplastic syndromes, acute myeloid leukemia, chronic

DNA hypomethylation Approved in China Mainland China
myelomonocytic leukemia

Idiopathic multicentric Castleman disease IL-6 antagonist Approved in China Greater China

High-risk neuroblastoma2 Anti-GD2 antibody Approved in China Mainland China

1. Approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 2. Conditionally approved. Full approval for these indications is contingent upon results from ongoing randomized, controlled confirmatory clinical
trials. 3. The approval is applicable to all 27 EU member states, plus Iceland, Lichtenstein and Norway. 4. U.S.: For patients with unresectable recurrent locally advanced or metastatic ESCC after prior systemic therapy. EU: For patients with advanced or metastatic ESCC after prior systemic chemotherapy and for
patients with NSCLC including: locally advanced or metastatic NSCLC after prior chemo, in combination with chemotherapy for 1L advanced or metastatic squamous NSCLC, and in combination with chemotherapy for 1L locally advanced or metastatic non-squamous NSCLC with no EGFR or ALK positive mutattions.

BLINCYTO®, KYPROLIS®, and XGEVA® are registered trademarks of Amgen or its subsidiaries.

18
 Growing Commercial Portfolio
WITH 16 APPROVED ASSETS

MECHANISM OF OUR COMMERCIAL

PRODUCT LEAD INDICATIONS REGULATORY STATUS PARTNER
ACTION RIGHTS

POBEVCY® Colorectal, lung, glioblastoma, ovarian, and cervical Anti-VEGF

Approved in China Greater China
(Avastin biosimilar) cancers antibody

TAFINLAR®
Melanoma and BRAF V600 Mutation NSCLC BRAF inhibitor Approved in China China Broad Markets6
(dabrafenib)

MEKINIST®
Melanoma and BRAF V600 Mutation NSCLC MEK inhibitor Approved in China China Broad Markets6
(trametinib)

VOTRIENT® Advance renal cell carcinoma VEGFR inhibitor Approved in China China Broad Markets6
(pazopanib)

AFINITOR® Advance renal cell carcinoma5, NET, SEGA and Breast

mTOR inhibitor Approved in China China Broad Markets6
(everolimus) cancer

ZYKADIA® ALK + NSCLC ALK inhibitor Approved in China China Broad Markets6
(ceritinib)

5. Following progression on or after vascular endothelial growth factor (VEGF)-targeted therapy. 6. Rights to promote and market in China's broad markets pursuant to a Market Development Agreement with an affiliate of Novartis Pharma AG. 7.
Conditionally approved. Full approval of any particular indication will depend on the results of required post-marketing study(ies) in China

Abbreviations: ALK = anaplastic lymphoma kinase; BLA = Biologics License Application; BRAF = B-rapidly accelerated fibrosarcoma; CLL = chronic lymphocytic leukemia; HCC = hepatocellular carcinoma; MCL = mantle cell lymphoma; MEK =
mitogen-activated protein kinase (MAPK) / Extracellular-signal regulated kinase (ERK); MSI = microsatellite instability-high; mTOR = Mammalian target of rapamycin; MZL = marginal zone lymphoma; NET = Neuroendocrine tumors; NPC =
nasopharyngeal carcinoma; NSCLC = non-small cell lung cancer; R/R = relapsed / refractory; SEGA = subependymal giant cell astrocytomas; SLL = small lymphocytic lymphoma; UC = urothelial carcinoma; VEGFR = vascular endothelial growth
factor receptor; WM = Waldenström’s macroglobulinemia
19
 Growing Commercial Revenue Stream

$ in mn
Marketed Product Revenue Q1 2023 Marketed Products Breakdown
(by product revenue)
$1400
$1,255

1200 5%
6%
1000
9% BRUKINSA®
800
$634
Tislelizumab
600
52% Amgen Products
400 $309 BMS Products
$223
200 $131 28% Other
$24
0

20
We Work Collaboratively with Our Partners, Large and Small, Regionally
and Globally, to Provide Innovative Medicines to Patients Faster

Multinational Corporations Small and Mid-sized Companies

Vebicorvir Acquired by Recordati (2021)

Qarziba, Sylvant
Vidaza, Revlimid BLINCYTO, KYPROLIS,
XGEVA
JV with SpringWorks
anti-LAG-3
anti-DKK1 Sitravatinib

Taflinar, Mekinist, Votrient, Affinitor, Zykadia

Tislelizumab, Ociperlimab Zanidatamab,
anti-CD70nt
ZW49

Access to Innovation Clinical Supply Agreements for Combination

Entry into cell therapy with Entry into mRNA Entry into LNP
iPSC-derived NK CAR therapeutics therapeutics
 Building State-of-the-Art Manufacturing to Support Global
Growth and Broad Portfolio

Multi-Functional Experienced, Biologics Future U.S. Manufacturing

Manufacturing Facility High-Quality Manufacturing Facility at the Princeton
in Suzhou Manufacturing Partners Facility in West Innovation Center, NJ
Guangzhou

• Aligned with the design • Manufacturing • Approved capacity 16,000L • Construction underway on a
criteria of U.S., EU, and China collaborations with U.S. manufacturing site
leading manufacturers • 54,000L completed in 2022 for biologic manufacturing
• Commercial-scale small in biologics and small + 10,000L in Q2 2023 and clinical development –
molecule drug products facility molecules complete by 1H 2024
• Building to 200,000L
• Pilot-scale biologic facility • 1 million+ sq ft of space for
future expansion
BeiGene became the first company to have two sites approved in China for a biologic product (tislelizumab)

22
 2023 Milestones and Catalysts
1H 2023 2H 2023
FDA decision on sNDA for
Approval
treatment of CLL/SLL

Approval Approvals in Australia for CLL/SLL

BRUKINSA®
Approval Approvals in China for TN CLL/SLL and WM
(zanubrutinib,
BTK Inhibitor) Approval Approvals in Canada for CLL/SLL

Regulatory submissions in US and EU for PFS

Regulatory submission
superiority vs. ibrutinib in R/R CLL - ALPINE

Approval Regulatory decision in US for 2L ESCC, in collaboration with Novartis*

Approval in China for 1L GC

Approval Approvals in China in 1L HCC
& for 1L ESCC

Approval In collaboration with Novartis EU 2L ESCC and 1/2L NSCLC decisions

Approval Approvals in Australia for NSCLC & 2L ESCC

Tislelizumab
(anti-PD-1 Ab) Regulatory submission Submissions in US for 1L gastric cancer & 1L ESCC in collaboration with Novartis

Regulatory submission BLA submission in Japan for 1L/2L ESCC

Data Announced positive Phase 3 trial in GC

Data Final analyses for 1L ES-SCLC

*U.S. FDA pre-approval manufacturing inspections for tislelizumab biologics license application (BLA) scheduled for completion by end of Q2
2023 Milestones and Catalysts (cont'd)
1H 2023 2H 2023
Initiate global pivotal trial in 1L CLL in
Study progress
BGB-11417 combo with BRUKINSA

(BCL-2)
Data readout Data readouts from ongoing studies

Data readout Readouts for multiple P2 studies, including: 2L ESCC in patients whose tumors
Ociperlimab express PD-(L)1, 1L HCC and 1L NSCLC
(anti-TIGIT Ab)
Study progress Complete enrollment in Ph3 AdvanTIG 302 in 1L NSCLC

BGB-16673 (BTK Degrader) Data readout Initial data readout from Phase I study in B cell malignancies

BGB-A445 (anti-OX40) Data readout Initial data readout for Phase 1 study in solid tumors

BGB-15025 (HPK1 inhibitor) Data readout Initiate dose expansion in combination with tislelizumab in solid tumors

LBL-007 (anti-LAG-3) Data

Study readout
progress Initiate patient dosing + tislelizumab in umbrella studies

Initiate 15 novel IO combos across 6 trials with tislelizumab including LAG3, OX40,
Additional Early Programs Study progress TIM3, TIGIT, and HPK1, targeting multiple new tumor types including HNSCC, CRC,
UBC, RCC, melanoma

24
Key Takeaways

BeiGene’s transformational next-generation model is leveraging unique global

1
opportunities created by worldwide industry changes.

We are building a global ecosystem of innovation, cost, and speed competitive

2 advantages that are designed to outperform key success indicators heralded
by our evolving industry.

We fight for life against cancer —internally and with partners— in the
3 unrelenting pursuit for exceptional science, quality, and impact by cost-
effectively driving global operational excellence.

4 We aspire to deliver improved medicines to more patients around the world,

more affordably.

25
Thank you
Appendix slides follow
 CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS (U.S. GAAP)
( A m o u n t s i n t h o u s a n d s o f U . S . d o l l a r s , e xc e p t f o r s h a r e s , A m e r i c a n D e p o s i t a r y S h a r e s ( A D S s ) , p e r s h a r e a n d p e r
ADS data)
Three Months Ended
March 31,
2023 2022 1

(Unaudited)
Revenue:
Product revenue, net $ 410,291 $ 261,573
Collaboration revenue 37,510 45,053
Total revenues 447,801 306,626
Expenses:
Cost of sales - products 81,789 65,237
Research and development 408,584 389,915
Selling, general and administrative 328,499 294,573
Amortization of intangible assets 187 188
Total expenses 819,059 749,913
Loss from operations (371,258) (443,287)
Interest income (expense), net 16,016 10,071
Other (loss) income, net 18,303 11,967
Loss before income taxes (336,939) (421,249)
Income tax expense 11,492 13,949
Net loss (348,431) (435,198)

Net loss per share attributable to BeiGene, Ltd.:

Basic and diluted $ (0.26) $ (0.33)
Weighted-average shares outstanding:
Basic and diluted 1,354,164,760 1,332,017,262

Net loss per ADS attributable to BeiGene, Ltd.:

Basic and diluted $ (3.34) $ (4.25)
Weighted-average ADSs outstanding:
Basic and diluted 104,166,520 102,462,866

1.We revised certain prior period financial statements for an error related to the valuation of net deferred tax assets, the impact of which was immaterial to our previously filed financial statements in the
first and second quarters of 2022 (see "Notes to the Condensed Consolidated Financial Statements, Note 1. Description of Business, Basis of Presentation and Consolidation and Significant Accounting 27
Policies" and "Note 2. Revision of Prior Period Financial Statements" included in our Quarterly Report on Form 10-Q for the period ended March 31, 2023 filed with the SEC).
Our Commitment to ESG

Our global strategy is focused on

five areas supported by ten
strategic priorities.

We have shared our progress

against our 2022 targets and
announce new goals in our 2022
ESG Report, which was published
in April.

28
 OUR PROGRESS
BeiGene made substantial progress in 2022 across all five Change Is the Cure focus areas and set a number of new goals.

Focus Area 2022 Goals 2022 Progress New Goals

 Continue to invest in medicines across multiple
modalities with 10 new molecules in clinic  Complete. Entered three new molecules in clinic
between 2022-2023

 Continue to seek approvals for our medicines  Complete. BRUKINSA approved in 19 new countries  10 new molecules in clinic annually
globally and regions in 2022 beginning in 2024

 Define pricing principles and affordability  Complete. Published BeiGene’s Position on

strategy Affordability

 Maintain colleague engagement scores

 Improve colleague engagement by three globally versus 2022 engagement scores
percent globally versus 2020 engagement  Complete. Improved by 7% with a stretch goal of +3% for the 2024
scores engagement survey
 Improve work-life balance survey scores by
3%, with a stretch goal of 5% in 2023
By 2030:
 Roll out a global initiative to address work-life  Complete. Rolling out a leadership-driven behavior  Reach global gender parity at the VP level
balance change program to improve work-life balance and above
 Achieve a 50% improvement in workforce
diversity (underrepresented groups)
company-wide at management levels in the
U.S.
 Develop a three-year global strategy to improve
 Complete. 2030 goals approved by Board of Directors  Continue to address the composition of the
DEI&B across the company
Board of Directors for gender and U.S.
underrepresented groups
29
 OUR PROGRESS (CONT'D)
BeiGene made substantial progress in 2022 across all five Change Is the Cure focus areas and set a number of new goals.
Focus Area 2022 Goals 2022 Progress New Goals
 Achieve ISO 14001 certifications for our  Set a quantitative Scopes 1 and 2
 Complete. Certification for each facility received in
Suzhou and Guangzhou manufacturing emissions goal by 2024
November 2022
facilities  Set a quantitative Scope 3 emissions goal
 Expand GHG inventory to include Scope 3 by 2025. To advance this goal, engage with
 Complete. Inventory compiled
emissions two-thirds of our raw material supplier base
 Conduct a climate risk scenario analysis and (based on 2021 spend information)
assessment aligned with the Task Force for  Complete. TCFD-aligned climate risk scenario analysis  Continued from 2022: Explore the creation
Climate-Related Financial Disclosures and assessment completed of a product stewardship program (This
(TCFD) recommendations goal is in progress as we continue to
evaluate internal product stewardship
 Set a global climate strategy  Complete. Strategy developed
efforts.)
 Develop a three-year patient engagement
 Complete. Strategy developed
and advocacy strategy
 Expand partnerships and collaborations with  Spearhead multi-stakeholder solutions that
 Complete. Launched Talk About It: Cancer and Mental
organizations around the world focused on empower patients and disrupt systemic
Health
health policy, equity, and patient needs access barriers by 2025
 Complete. Piloted a paid volunteer time-off policy in the  Engage employees in 10,000 hours of
 Launch colleague engagement and volunteer
U.S.; organized colleague engagement events in U.S., global volunteerism by 2023
events in the U.S., Europe, and Australia
Europe, Australia, and China  Expand paid volunteer time-off policy
 Engage employees to support organizations globally in 2023
 Complete. Employees participated in numerous events
focused on cancer awareness raising,
to support patient organizations
patient support, and research

 Continued from 2022: Implement a third-

 Become a signatory of the UN Global  Complete. Joined in May 2022 party supplier risk management program in
Compact  Participating in the UN Global Compact’s SDG 2023 (Manager hired in 2022 to oversee
Ambition Accelerator development and implementation)

30